Comparative Pharmacology
Head-to-head clinical analysis: NEPHROSCAN versus TECHNETIUM TC 99M TSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROSCAN versus TECHNETIUM TC 99M TSC.
NEPHROSCAN vs TECHNETIUM TC 99M TSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
Technetium Tc 99m TSC is a radiopharmaceutical that binds to activated leukocytes, primarily neutrophils, via interaction with integrin receptors (e.g., CD11b/CD18), allowing imaging of inflammation and infection.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
1-10 mCi (37-370 MBq) intravenously as a single dose for imaging studies; dose depends on indication and imaging protocol.
None Documented
None Documented
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life approximately 6 hours; allows for same-day imaging but requires prompt scanning due to radionuclide decay.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Renal: ~50% excreted unchanged in urine within 24 hours; remainder eliminated via hepatobiliary system into feces.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical